• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Paragon 28 Introduces a Novel Right-Angle Drill for the APEX 3D™ Total Ankle Replacement System

    9/10/24 9:00:00 AM ET
    $FNA
    Medical/Dental Instruments
    Health Care
    Get the next $FNA alert in real time by email

    Paragon 28, Inc. (NYSE:FNA) is pleased to announce the addition of a novel Right-Angle Drill to the APEX 3D™ Total Ankle Replacement System designed to improve tibia preparation prior to the implantation of the APEX 3D™ tibia implant. The Right-Angle Drill utilizes a linear guide to precisely drill vertical holes into the tibia for ideal peg placement and a highly stable tibia implant interface.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910193295/en/

    Figure 1: Image of the APEX 3D Right-Angle Drill as a standalone unit. (Graphic: Business Wire)

    Figure 1: Image of the APEX 3D Right-Angle Drill as a standalone unit. (Graphic: Business Wire)

    The release of the Right-Angle Drill continues a series of instrumentation enhancements to the APEX 3D™ Total Ankle Replacement System, which includes the recently released Polishing Blocks, Square Tip Drill, and next-generation Off-Set Impaction Handle. These recent enhancements were primarily designed to improve tibia preparation, thereby contributing to the long-term success of ankle replacements and ultimately improving surgeon experience and patient outcomes.

    "The preparation of the tibia prior to placing the implant is paramount for long-term success. Successful total ankle surgery is characterized by an implant bone interface, prepared tibia bone and the tibia implant, which combine into one structure that works together," says Dr. Mark Myerson, a design surgeon of the APEX 3D™ system. "The Right-Angle Drill precisely prepares the tibia to create the appropriate interface for the APEX 3D™ implant to allow for long-term survival."

    "We are thrilled to continue advancing our APEX 3D™ Total Ankle Replacement System with the launch of our novel Right-Angle Drill," says Albert DaCosta, CEO and Chairman of Paragon 28. "The Right-Angle Drill is a critical step towards addressing tibia implant loosening, the primary cause of total ankle replacement failure. This drill enables surgeons with a more precise preparation and promotes better implant integration, which we believe will result in improved long-term outcomes for foot and ankle patients."

    Paragon 28 will be showcasing the APEX Right-Angle Drill at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting this week in Vancouver, British Columbia. Additionally, Paragon 28 will be showcasing the recently launched R3FLEX™ Stabilization System, SMART28℠ Case Management Portal, SMART Bun-Yo-Matic℠, FJ2000™ Power Console and Burr System, and PRECISION® MIS Bunion System throughout the meeting. Surgeons may visit booth 625 or schedule a hands-on introduction to these technologies with P28 product experts who will be on-site throughout the meeting.

    About Paragon 28, Inc.

    Based in Englewood, CO., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.

    Forward Looking Statements

    Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Paragon 28's potential to shape a better future for foot and ankle patients. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. Forward-looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward-looking statements are based on Paragon 28's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Paragon 28's business in general, see Paragon 28's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K/A for the fiscal year ended December 31, 2023 and its Quarterly Reports on Form 10-Q, as updated periodically with its other filings with the SEC. These forward-looking statements are made as of the date of this press release, and Paragon 28 assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

    Disclaimer

    Dr. Myerson may report consulting and royalty fees from Paragon 28 in connection with the provision of product development services to Paragon 28.

    Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240910193295/en/

    Get the next $FNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FNA

    DatePrice TargetRatingAnalyst
    1/29/2025Buy → Hold
    Needham
    1/29/2025Outperform → Mkt Perform
    William Blair
    9/29/2023Outperform
    William Blair
    4/11/2023$23.00Overweight
    Stephens
    12/14/2022$32.00Buy
    B. Riley Securities
    3/9/2022$30.00 → $25.00Buy
    B of A Securities
    3/9/2022$25.00 → $23.00Buy
    Canaccord Genuity
    2/9/2022$31.00 → $25.00Buy
    Needham
    More analyst ratings

    $FNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Paragon 28 downgraded by Needham

    Needham downgraded Paragon 28 from Buy to Hold

    1/29/25 2:02:26 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    Paragon 28 downgraded by William Blair

    William Blair downgraded Paragon 28 from Outperform to Mkt Perform

    1/29/25 7:36:30 AM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    William Blair initiated coverage on Paragon 28

    William Blair initiated coverage of Paragon 28 with a rating of Outperform

    9/29/23 7:20:32 AM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    $FNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Paragon 28 to Showcase Recent Product Launches at The American College of Foot and Ankle Surgeons Annual Conference

    Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference. From March 27-29, Paragon 28 will feature a suite of recently launched products designed to improve foot and ankle patient outcomes and surgeon experience. "We are thrilled to engage with foot and ankle specialists at ACFAS and showcase our latest innovations after an incredibly strong product launch cadence in 2024," said Albert DaCosta, CEO of Paragon 28. "Our progress and innovation in the space is a testament to our mission to continuous

    3/24/25 4:05:00 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act

    Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") in connection with the previously announced acquisition of Paragon 28 by Zimmer Biomet Holdings, Inc. (NYSE:ZBH) ("Zimmer Biomet"). The expiration of the waiting period under the HSR Act represents a significant milestone in the regulatory approval process, satisfying one of the conditions required to complete the proposed merger with Zimmer Biomet. With the HSR Act waiting period expired, the transaction now re

    3/11/25 4:01:00 PM ET
    $FNA
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    Paragon 28 to Feature Several Recent Product Launches at The American Academy of Orthopaedic Surgeons Annual Conference

    Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American Academy of Orthopaedic Surgeons ("AAOS"). From March 10th – 14th, Paragon 28 will feature a suite of recently launched products intended to enhance patient outcomes and the surgeon experience, including: SMART 28℠ Case Management Portal featuring SMART Bun-Yo-Matic℠ Digital case management platform designed to streamline surgical planning and execution, integrating AI, data analytics, and 3D modeling​. Provides an intuitive interface for case scheduling, direct communication with engineers, and conversion o

    3/7/25 4:32:00 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    $FNA
    SEC Filings

    View All

    SEC Form S-8 POS filed by Paragon 28 Inc.

    S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

    4/21/25 4:24:46 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Paragon 28 Inc.

    S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

    4/21/25 4:23:46 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Paragon 28 Inc.

    S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

    4/21/25 4:22:43 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    $FNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Dacosta Albert returned 11,753,724 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Paragon 28, Inc. (0001531978) (Issuer)

    4/21/25 5:00:07 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    Director Wright Kristina returned 32,118 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Paragon 28, Inc. (0001531978) (Issuer)

    4/21/25 5:00:10 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Jarboe Matthew returned 575,320 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Paragon 28, Inc. (0001531978) (Issuer)

    4/21/25 5:00:14 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    $FNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Dacosta Albert bought $255,226 worth of shares (28,000 units at $9.12) (SEC Form 4)

    4 - Paragon 28, Inc. (0001531978) (Issuer)

    3/18/24 5:34:02 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    Dacosta Albert bought $259,555 worth of shares (30,500 units at $8.51) (SEC Form 4)

    4 - Paragon 28, Inc. (0001531978) (Issuer)

    11/13/23 8:00:07 AM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    $FNA
    Leadership Updates

    Live Leadership Updates

    View All

    Paragon 28 Appoints Dave Demski to Board of Directors

    Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi

    12/11/24 9:00:00 AM ET
    $ATEC
    $FNA
    Medical/Dental Instruments
    Health Care

    Appointment of Stephen M. Deitsch as new Chief Financial Officer

    OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer ("CFO") on April 8, 2024. Steve joins OrganOx from Paragon 28 (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopaedic market, where he has held the role of CFO since September 2020. Steve's leadership was instrumental in Paragon 28's successful IPO on the NYSE in the fall of 2021. Prior to Paragon 28, Steve held CFO r

    4/4/24 11:43:23 AM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    Paragon 28 Announces Appointment of Meghan Scanlon to Board of Directors

    Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of Meghan Scanlon to its Board of Directors. Ms. Scanlon has joined the Board's Compensation and Quality, Technology and Regulatory Committees. Ms. Scanlon has more than 20 years of senior leadership experience with global medical device companies. She currently serves as senior vice president and president, Urology and Pelvic Health, for Boston Scientific Corporation and is a member of the Boston Scientific Executive Committee. Ms. Scanlon also is a member of the Boston Scientific Global Council for Inclusion, serving as the executive sp

    3/28/22 4:02:00 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    $FNA
    Financials

    Live finance-specific insights

    View All

    Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results

    Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basisFourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basisFull-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00Company provides full-year 2025 financial guidanceWARSAW, Ind., Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024.  The Company reported fourth quarter net sales of $2.023 billion, an increase of 4.3% over

    2/6/25 6:30:00 AM ET
    $FNA
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    Paragon 28 Reports Third Quarter 2024 Financial Results and Raises 2024 Net Revenue Guidance

    Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2024 and raised its 2024 net revenue guidance. Recent Business Updates Recorded global net revenue of $62.3 million in the third quarter, representing 18.1% and 17.6% reported and constant currency growth compared to the prior year period, respectively Raised net revenue guidance to $252 million to $256 million for full year 2024 net revenue, representing 16.5% to 18.3% reported growth compared to 2023 Drove a 969 basis point improvement in operating expense as a

    11/12/24 4:05:00 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    Paragon 28 To Report Third Quarter 2024 Financial Results on November 12, 2024

    Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 12, 2024. The Company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. Live audio of the webcast will be available on the "Investors" section of the Company's website at: ir.paragon28.com. The

    10/17/24 4:05:00 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    $FNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Paragon 28 Inc.

    SC 13G - Paragon 28, Inc. (0001531978) (Subject)

    8/9/24 9:02:32 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Paragon 28 Inc. (Amendment)

    SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)

    2/14/24 3:29:50 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Paragon 28 Inc. (Amendment)

    SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)

    2/13/24 4:23:50 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care